Matheus da Silva Souza

Matheus da Silva Souza

Auto-generated profile, based on publicly available information

Matheus da Silva Souza

Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of Molecular Structure
Verified
Journal Article
Closed access
LDLuan F. Diniz
Luan F. Diniz
MSMatheus S. Souza
Matheus S. Souza
PCPaulo S. Carvalho
Paulo S. Carvalho
CSCecilia C.P. da Silva
Cecilia C.P. da Silva
DRD'Vries Fernando Richard
D'Vries Fernando Richard
Javier Alcides EllenaJavier Alcides Ellena
Javier Alcides Ellena

4 January 2019 in Crystal Growth & Design
Verified
Journal Article
Closed access
BOBolaji C. Dayo Owoyemi
Bolaji C. Dayo Owoyemi
CSCecilia C. P. da Silva
Cecilia C. P. da Silva
MSMatheus S. Souza
Matheus S. Souza
LDLuan F. Diniz
Luan F. Diniz
Javier Alcides EllenaJavier Alcides Ellena
Javier Alcides Ellena
RCRenato L. Carneiro
Renato L. Carneiro

12 July 2018 in Crystal Growth & Design
Verified
Journal Article
Closed access
MSMatheus S. Souza
Matheus S. Souza
LDLuan F. Diniz
Luan F. Diniz
LVLautaro Vogt
Lautaro Vogt
PJPaulo S. Carvalho Jr.
Paulo S. Carvalho Jr.
DRD'Vries Fernando Richard
D'Vries Fernando Richard
Javier Alcides EllenaJavier Alcides Ellena
Javier Alcides Ellena

14 June 2018 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
CSCecilia C. P. da Silva
Cecilia C. P. da Silva
CMCristiane C. de Melo
Cristiane C. de Melo
MSMatheus S. Souza
Matheus S. Souza
LDLuan F. Diniz
Luan F. Diniz
RCRenato L. Carneiro
Renato L. Carneiro
Javier Alcides EllenaJavier Alcides Ellena
Javier Alcides Ellena

25 March 2019 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
PCPaulo S. Carvalho
Paulo S. Carvalho
LDLuan F. Diniz
Luan F. Diniz
JTJuan C. Tenorio
Juan C. Tenorio
MSMatheus S. Souza
Matheus S. Souza
Chris Hebert J FrancoChris Hebert J Franco
Chris Hebert J Franco
Javier Alcides EllenaJavier Alcides Ellena
Javier Alcides Ellena
Paroxetine hydrochloride, PRX HCl, is an important and widely prescribed antidepressant drug for anxiety and depression treatment. Since hydrochloride salts can cause problems in their manufacture, we have designed organic salts with oxalic, fumaric, maleic and L-tartaric acids based on the NH2 +⋯COO− synthon. All the salts were obtained from an innovative anion exchange method: selective crystallization from a mixture of PRX HCl and an acid in a certain ratio. The crystal structures of paroxetine (PRX) salts with dicarboxylic acids were determined by the single-crystal X-ray diffraction (SCXRD) method and were also analysed by thermogravimetric analysis, differential scanning calorimetry and FT-IR spectroscopy. Except for FUM and MAL acids, all the carboxylic acids form hydrate salts. Oxalate and tartrate salts are formed through the complete protonation of the anion and exhibit a 1 : 2 stoichiometry. All structures have a Z′ > 1 and different conformations are found for the PRX molecules. In general, the ionic units in the salts extend into chains that pack cohesively, via CH⋯O and CH⋯π interactions, into layers. The oxalate salt forms a channel structure where H2O molecules are hosted. On the other hand, the presence of water molecules in the tartrate salt allows the packing of ionic layers. The organic salts are thermally more stable than the commercial PRX form, m.p. > 143 °C. They exhibit lower solubility compared to the hydrochloride form. The scientific contributions of this study show the diversity of the PRX solid forms and identify candidates for use in new antidepressant API solid formulations.

2 January 2019 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
BOBolaji C. Dayo Owoyemi
Bolaji C. Dayo Owoyemi
CSCecilia C. P. da Silva
Cecilia C. P. da Silva
LDLuan F. Diniz
Luan F. Diniz
MSMatheus S. Souza
Matheus S. Souza
Javier Alcides EllenaJavier Alcides Ellena
Javier Alcides Ellena
RCRenato Lajarim Carneiro
Renato Lajarim Carneiro
Fluconazole (FLZ) is one of the most used antifungal drugs worldwide and has been the focus of various investigations with the aim of enhancing its biomedical application. Most of the new solid forms achieved for this drug were determined by powder X-ray diffraction, and a few reports on polymorphs, solvates, cocrystals, and one salt–cocrystal by single-crystal X-ray diffraction (SCXRD) are available. By considering that FLZ is a very weak base (pKa = 1.76, when protonated), salt formation with this drug is expected with the use of very strong organic acids, in order to dislocate the proton from the acid to the FLZ. To the best of our knowledge, only one organic salt of FLZ with picric acid (pKa = 0.38) and one salt–cocrystal (maleate–maleic, pK a1 = 1.92) were reported by SCXRD until now. Having in mind all the advantages that pharmaceutical salts have in drug delivery, in this work we depict the methodology and techniques employed to synthesize a new salt of FLZ using oxalic acid (pK a1 = 1.23). The screening process was initially monitored using Raman spectroscopy, while further characterization by X-ray diffraction (powder and single crystal) and thermal analysis (DSC and TG) was performed to confirm the new salt fluconazolium oxalate (1 : 1). Finally, salt equilibrium solubility studies confirmed an improvement, about 7-fold, when compared to the commercialized active pharmaceutical ingredient (polymorph II). In addition, this is the first reported GRAS (generally regarded as safe) salt of the antifungal drug fluconazole.